查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832478

伴随诊断市场（按产品类型、应用、最终用户和分销管道）—全球预测，2025-2032

Companion Diagnostics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年伴随诊断市场将成长至 169.1 亿美元，复合年增长率为 11.06%。

主要市场统计数据
基准年2024年 73亿美元
预计2025年 81亿美元
预测年份：2032年 169.1亿美元
复合年增长率（%） 11.06%

权威介绍伴随诊断如何重新定义临床路径以及诊断、治疗和医疗保健交付中的策略价值

伴随诊断正在改变实验室科学与临床决策的交叉领域，使患者分层和标靶治疗选择更加精准。该领域已从最初仅支持单药联合治疗的小众领域发展成为现代精准医疗策略的重要组成部分，影响着监管审查路径、临床试验设计和商业性价值提案。随着生物标记和伴随检测在治疗研发中日益占据优先地位，诊断工具正从辅助产品转变为影响治疗流程和付款人互动的策略资产。

同时，技术进步和跨学科合作正在拓展伴随诊断的应用范围。分子谱分析、数位病理学和数据分析领域的创新产生了更丰富的诊断讯号，为治疗方法选择和长期疾病管理提供资讯。本简介概述了影响伴随诊断格局的因素，概述了临床效用和商业性应用之间的相互关係，并提出了相关人员如何使其营运能力与不断变化的临床和监管要求相协调的期望。

分子技术进步、监管调整和综合临床工作流程如何重塑伴随诊断和临床应用

在技​​术、法规和临床实践融合的推动下，伴随诊断领域正在经历一场变革。定序技术和多重检测的进步正在扩展诊断范围，使临床医生能够从单一分析物检测转向全面的分子分析，从而捕捉复杂的疾病生物学特征。这种演变，加上现实世界证据和自适应临床试验框架的日益普及，正在缩短从生物标记发现到临床应用的时间，并为迭代检验创造新的机会。

法律规范正在适应这些进步，强调分析的稳健性、临床有效性和上市后证据的产生。付款人和医疗保健系统正在重新调整报销模式，以体现诊断主导的治疗价值，而开发商也面临着证明成本效益和改善患者预后的压力。同时，数位化整合和实验室自动化正在缩短週转时间，提高可重复性，增强临床医生的信心，并支援更广泛的工作流程整合。这些转变正在增强诊断在精准医疗中的作用，同时也为商业化策略、供应链规划和相关人员的证据产生带来了复杂性。

随着诊断技术的成熟，诊断开发商、製药赞助商和临床实验室之间的伙伴关係也变得更加策略化和复杂化。证据共同产生和共同开发契约使市场策略更加协调一致，而数据共用联盟则加速了生物标记的检验。这些趋势标誌着一个更整合的生态系统的出现，在这个生态系统中，诊断不仅可以为治疗决策提供讯息，而且在临床开发和上市规划中发挥核心作用。

评估不断变化的关税政策对诊断供应链、筹资策略和实验室营运弹性的系统性影响

近期政策週期中宣布或实施的贸易政策变化和关税措施，为伴随诊断供应链带来了新的变量，影响了试剂采购、设备采购和国际实验室伙伴关係。对检测设备、昂贵的定序仪器和进口试剂征收的关税改变了供应商的选择动态，并可能刺激在地采购策略。为此，许多相关人员已开始重新评估供应商关係，避免关键投入的双重采购，并探索在地化生产方案，以减轻贸易相关成本波动的影响。

除了直接采购成本外，关税还影响依赖进口设备的临床检测和诊断製造商的资本规划。采购週期正在发生变化，买家为了避开关税窗口而推迟或加快采购，而供应商则重新评估其管道策略以保持竞争力。此外，关税引发的物流和海关处理变化可能会影响前置作业时间，进而影响库存管理和对临床合作伙伴的服务水准承诺。在这种情况下，拥有灵活供应结构和本地製造及分销能力的公司更有能力在不牺牲服务品质的情况下维持业务。

相关人员应从系统视角审视关税的影响，不仅要考虑成本压力，还要考虑贸易流变化所带来的营运摩擦。战略应对措施包括与供应商重新协商长期合同，以应对意外关税；在监管途径允许的情况下投资本地组装和试剂混合；以及加强情景规划以预测未来的贸易变化。这些措施将有助于在外部政策波动的情况下保持检测服务的连续性，并支持稳健的商业化路径。

细分市场主导的洞察，将检测方式、临床应用、用户需求和分销管道结合起来，为产品开发和商业化策略提供讯息

有效的細項分析能够揭示技术优势及其与临床需求和机会的交集。从检测方式的角度来看，免疫组织化学技术能够提供成熟的组织生物标记读数，并且仍然是许多病理学工作流程中不可或缺的一部分。次世代定序拓展了诊断的广度和深度，并进一步细分为标靶定序（专注于与可操作变异比对的特定基因组合）；转录组定序（捕获与机制阐明和抗药性监测相关的基因表现表现谱）；以及全基因组定序（为复杂病例提供全面的基因组图谱）。聚合酶炼式反应因其速度和灵敏度而持续受到关注，并有专门的形式，例如用于绝对定量的数位PCR和用于高通量相对定量的定量PCR。

以应用为中心的细分揭示了测试在哪些领域推动临床决策，以及开发资源应集中在何处。遗传性疾病提供了早期检测和家庭风险评估的机会；感染疾病需要快速灵敏的病原体鑑定和抗药性分析平台；肿瘤学透过精准标靶治疗，继续成为伴随诊断的主要临床驱动力；药物药物基因体学则支持跨治疗领域更安全、更有效的药物选择。每种应用都有不同的分析要求和检验范式，影响技术选择和临床实施策略。

终端用户细分决定了销售模式和服务交付预期。学术和研究机构通常优先考虑发现和转化工作的灵活性和分析深度，而诊断实验室则强调通量、合规性和可重复性。医院将检测整合到临床工作流程中，并优先考虑週转时间和临床报告，而製药公司则优先考虑与伴随诊断和治疗产品线以及临床试验整合的衔接。市场区隔进一步影响市场进入，直接竞标安排支援临床现场采购，经销商销售促进更广泛的地理覆盖，线上销售支援在分散式检测环境中快速订购套件和耗材。这些细分提供了产品市场契合度的多层次视角，并指南了在开发、商业化和客户支援方面投资的优先顺序。

医疗保健基础设施、监管方法和战略伙伴关係将如何推动美洲、中东和北非以及亚太地区的差异化采用模式？

伴随诊断的区域动态受不同的医疗基础设施、监管方式和投资生态系统的影响。在美洲，整合的医疗服务提供者、强大的临床试验网络以及庞大的生物技术部门促进了新型诊断方法的早期应用，并促进了临床医生与产业之间的密切合作。这种环境支持将研究与临床路径连接起来的迭代检验和临床效用研究，而报销谈判也越来越强调已证实的价值和疗效的一致性。

欧洲、中东和非洲地区的应用曲线各不相同，这主要受监管环境和支付方趋势的影响。欧洲部分地区拥有强大的学术中心和集中式公共卫生系统，能够促进多中心合作和标准化工作，而中东和北非市场则更注重能力建设、实验室基础设施现代化和区域协调。跨境伙伴关係和诊断中心在将先进检测能力扩展到这些地区更广泛的患者群体方面发挥关键作用。

亚太地区以其实验室基础设施的快速投资、国内诊断製造业的成长以及庞大的患者群体而着称，这些因素有助于转化研究和真实世界证据的产生。政府主导的精准医疗计画扩展计画以及大型临床中心的存在为扩展诊断服务创造了机会。相关人员必须应对不同地区的监管时间表、报销框架和基础设施限制，根据当地实际情况定制市场准入和伙伴关係策略，同时利用全球证据产生来支持更广泛的应用。

深入了解竞争定位、伙伴关係和能力堆栈，这些将决定诊断开发人员、实验室和全方位服务供应商的成功

伴随诊断领域的竞争由专业的检测试剂开发商、仪器製造商、临床实验室网路以及综合诊断和治疗伙伴关係共同推动。在分析化学、分子生物学和病理学领域拥有深厚专业知识的公司利用专有平台和检验的工作流程来建立临床可靠性。同时，拥有可扩展生产、监管经验和协作开发模式的公司展现出加速伴随检测试剂临床应用和市场开发的能力。

诊断开发商与药品赞助商之间的策略联盟仍然是共同开发与治疗方法密切相关的检测方法的重要途径。此类伙伴关係通常延伸至证据产生、编码和报销策略以及上市后监管。此外，提供端到端检测能力（包括集中式和分散式服务模式）的实验室服务供应商在创新与临床可及性之间的桥樑中发挥关键作用。投资于稳健品质系统、与电子健康记录的互通性以及面向临床医生的报告工具​​的公司往往能够实现更高的采用率并更好地融入到医疗护理途径中。

新的竞争压力将来自那些将诊断技术与先进的分析和决策支援解决方案相结合，从而对生物标记数据进行更具可操作性的纵向解读的公司。这些混合产品标誌着市场转向将分析绩效与临床效用和工作流程效率相结合的价值提案，从而为那些能够在患者管理和医疗系统结果方面取得切实改善的机构带来回报。

诊断开发人员和健康系统需要采取切实可行的策略措施，协调创新、供应链弹性和证据共同生成

为了有效应对不断变化的诊断领域，产业领导者应优先考虑以下几项策略要务。首先，开发能够证明临床实用性和操作可行性的产品，具体方法是将最终用户需求纳入检测设计，在代表性效用中检验效能，并确保与临床决策流程整合。这种协调可以减少实施过程中的摩擦，并支持与付款方就改善结果而非分析创新进行讨论。

其次，透过多元化供应商、尽可能考虑本地製造和组装，以及将关税和物流方案纳入采购计划，以增强供应链的韧性。积极主动的供应商伙伴关係以及包含应急条款的长期合同，可以降低贸易和分销中断的风险，并支持实验室的可靠运作。

第三，与药品申办方、临床网络和卫生系统建立策略合作，共同产生证据，加速临床整合。此类合作应建构风险共用机制，并围绕可证实的患者获益调整奖励。对数据基础设施和分析能力的投资将有助于产生更具说服力的真实世界证据，并持续监测其绩效。

最后，投资于能够反映最终用户实际情况的商业化模式。这包括混合分销模式，将与医疗服务提供者的直接接触、与分销商的合作以及耗材的数位管道相结合。将产品创新与临床医生教育、付款人参与计画和精简的监管策略相结合，可以提高产品成功推广和持续临床使用的可能性。

透明的混合方法研究框架，结合专家访谈、监管文件分析和案例研究综合​​，以产生可操作的诊断见解

本研究采用定性和定量相结合的方法，以全面了解伴随诊断领域的现状。主要内容包括与临床意见领袖、实验室主任、监管专家和商业性相关人员的访谈，以了解营运挑战、应用驱动因素以及未满足的临床需求。这些访谈为评估分析平台、检测效能特征以及实际临床工作流程中的整合障碍提供了一个框架。

二次研究包括广泛检索同侪审查文献、监管指导文件、临床实践指南和公共声明，以便在当前的科学和监管环境下进行分析。本研究对成功的诊断和治疗联合开发案例进行了比较分析，以识别证据生成、监管策略和市场进入计划方面的最佳实践和通用陷阱。

我们对主要和次要研究结果进行了三角综合，以得出基于情境的供应链设计、商业化路径和区域参与策略的启示。与行业相关人员举行了检验研讨会，以完善结论并确保其实践相关性。这种混合方法设计强调假设的透明度、洞察对输入来源的可追溯性，以及根据组织决策需求量身定制的可操作建议。

简明结论综合了技术、监管和商业性要求，以指导伴随诊断​​的策略投资和临床整合

摘要：伴随诊断正在重塑临床路径、临床试验设计和商业模式，在精准医疗中日益重要。定序和多重检测技术的进步，加上监管和报销机制的持续演进，正在提升人们对临床效用和营运准备度的期望。供应链和贸易政策的动态变化增加了复杂性，使得韧性和策略采购成为商业化计画的关键要素。

按产品类型、应用程式、最终用户和分销管道进行细分，有助于明确开发和上市要求，而区域动态则需要製定独特的策略，以反映基础设施、法规和付款方的差异。那些将卓越的分析能力与强大的证据生成、策略伙伴关係以及与临床医生一致的彙报和工作流程整合相结合的组织将获得竞争优势。总而言之，这些见解为寻求优先考虑伴随诊断投资并推动临床整合的领导者提供了清晰的基础。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 将多组体学物标记整合到伴随诊断检测中以实现个人化治疗
  • 扩展基于液态生物检体的伴随诊断，用于即时治疗监测
  • 采用数位病理学和人工智慧演算法解释伴随诊断结果
  • 製药公司和诊断开发公司合作共同开发标靶治疗
  • 新兴市场中成本效益高的POC伴随诊断平台的出现
  • 监管协调倡议将简化重点地区的伴随诊断核准
  • 开发能够同时分析多种生物标记的多重伴随诊断
  • 增加对次世代定序面板的投资，用于全面的伴随诊断测试

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章伴随诊断市场（依产品类型）

  • 免疫组织化学
  • 原位杂交
  • 次世代定序
    • 标靶定序
    • 转录组定序
    • 全基因组序列分析
  • 聚合酵素链锁反应
    • 数位PCR
    • 定量PCR

第九章伴随诊断市场（按应用）

  • 遗传性疾病
  • 感染疾病
  • 肿瘤学
  • 药物基因组学

第 10 章 伴随诊断市场（依最终使用者）

  • 学术研究机构
  • 诊断实验室
  • 医院
  • 製药公司

第 11 章伴随诊断市场（依通路）

  • 直接竞标
  • 经销商销售
  • 网上销售

第十二章 伴随诊断市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 伴随诊断市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 伴随诊断市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Abbott Laboratories
    • Illumina, Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Agilent Technologies, Inc.
    • Siemens Healthineers AG
Product Code: MRR-433AB1DC2871

The Companion Diagnostics Market is projected to grow by USD 16.91 billion at a CAGR of 11.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.30 billion
Estimated Year [2025] USD 8.10 billion
Forecast Year [2032] USD 16.91 billion
CAGR (%) 11.06%

An authoritative introduction to how companion diagnostics are redefining clinical pathways and strategic value across diagnostics, therapeutics, and healthcare delivery

Companion diagnostics are changing the interface between laboratory science and clinical decision-making, enabling more precise patient stratification and targeted therapy selection. The field has matured from a niche enabler of single-drug pairings to an integral component of modern precision medicine strategies, influencing regulatory review pathways, clinical trial designs, and commercial value propositions. As therapeutic development increasingly prioritizes biomarkers and companion tests, diagnostic tools have transitioned from adjunctive products to strategic assets that shape treatment algorithms and payer conversations.

In parallel, technological advances and cross-disciplinary collaborations have broadened the applications of companion diagnostics. Innovations in molecular profiling, digital pathology, and data analytics have created richer diagnostic signals that inform both therapeutic selection and longitudinal disease management. This introduction outlines the drivers shaping the companion diagnostics environment, frames the interplay between clinical utility and commercial adoption, and sets expectations for how stakeholders can align operational capabilities with evolving clinical and regulatory demands.

How converging advances in molecular technology, regulatory adaptation, and integrated clinical workflows are reshaping companion diagnostics and clinical adoption

The companion diagnostics landscape is undergoing transformative shifts driven by converging forces in technology, regulation, and clinical practice. Advances in sequencing technologies and multiplexed assays have expanded the diagnostic repertoire, enabling clinicians to move beyond single-analyte tests toward comprehensive molecular profiling that captures complex disease biology. This evolution is paired with increasing acceptance of real-world evidence and adaptive clinical trial frameworks, which together compress the timeline from biomarker discovery to clinical adoption and create new opportunities for iterative validation.

Regulatory frameworks are adapting to these advances, with agencies emphasizing analytical robustness, clinical relevance, and post-market evidence generation. Payers and health systems are recalibrating reimbursement models to consider diagnostic-driven therapeutic value, prompting developers to demonstrate cost-effectiveness and patient outcome improvements. At the same time, digital integration and laboratory automation are reducing turnaround times and improving reproducibility, which enhances clinician confidence and supports broader workflow integration. These shifts collectively elevate the role of diagnostics in precision medicine while also introducing complexity in commercialization strategies, supply chain planning, and cross-stakeholder evidence generation.

As diagnostics mature, partnerships between diagnostic developers, pharmaceutical sponsors, and clinical laboratories are becoming more strategic and sophisticated. Collaborative evidence generation and co-development agreements are enabling more aligned go-to-market strategies, while data-sharing consortia are accelerating biomarker validation. These trends signal a more integrated ecosystem in which diagnostics not only inform therapeutic decisions but also play a central role in clinical development and market access planning.

Assessing the systemic consequences of evolving tariff policies on diagnostics supply chains, procurement strategies, and laboratory operational resilience

Trade policy shifts and tariff measures announced or implemented in recent policy cycles have introduced new variables into the supply chains that underpin companion diagnostics, with implications for reagent procurement, instrument sourcing, and international laboratory partnerships. Tariffs on laboratory equipment, high-value sequencing instruments, and imported reagents can alter supplier selection dynamics and motivate localized sourcing strategies. In response, many stakeholders have started reassessing vendor relationships, dual-sourcing critical inputs, and exploring regionalized manufacturing options to mitigate exposure to trade-related cost volatility.

Beyond direct procurement costs, tariffs influence capital planning for clinical laboratories and diagnostic manufacturers that rely on imported instrumentation. Procurement cycles are adapting as buyers delay or accelerate purchases to navigate tariff windows, and vendors are revising channel strategies to preserve competitiveness. Moreover, tariff-driven changes in logistics and customs processing can affect lead times, which in turn influence inventory management and service level commitments to clinical partners. In this context, firms with flexible supply arrangements and in-region manufacturing or distribution capabilities are better positioned to sustain operations without sacrificing service quality.

Stakeholders should view tariff impacts through a systems lens, considering not only incremental cost pressures but also the operational friction that arises from altered trade flows. Strategic responses include renegotiating long-term supplier contracts with tariff contingencies, investing in local assembly or reagent blending where regulatory pathways permit, and enhancing scenario planning to anticipate future trade shifts. These measures help maintain continuity of testing services and support resilient commercialization pathways despite external policy fluctuations.

Segment-driven insights that align assay modality, clinical application, user needs, and distribution channels to inform product development and commercialization strategies

Effective segmentation analysis illuminates where technical strengths intersect with clinical demand and commercial opportunity. When products are viewed through the lens of assay modality, Immunohistochemistry offers established tissue-based biomarker readouts that remain essential for many pathology workflows, while In Situ Hybridization complements tissue analysis with nucleic acid localization. Next Generation Sequencing expands diagnostic breadth and depth and is further differentiated by Targeted Sequencing, which focuses on specific gene panels aligned to actionable variants; Transcriptome Sequencing, which captures gene expression profiles relevant to mechanism elucidation and resistance monitoring; and Whole Genome Sequencing, which provides comprehensive genomic context for complex cases. Polymerase Chain Reaction retains prominence for its speed and sensitivity and includes specialized forms such as Digital PCR for absolute quantitation and Quantitative PCR for high-throughput relative quantitation.

Application-focused segmentation reveals where testing drives clinical decision-making and where development resources should be concentrated. Genetic Disorders present opportunities for early detection and family risk assessment, Infectious Diseases require rapid, sensitive platforms for pathogen identification and resistance profiling, Oncology continues to be the dominant clinical driver for companion diagnostics through precise targeting of therapies, and Pharmacogenomics supports safer and more effective medication selection across therapeutic areas. Each application imposes distinct analytical requirements and validation paradigms, influencing both technology choice and clinical implementation strategies.

End-user segmentation shapes distribution models and service delivery expectations. Academic and research institutes often prioritize flexibility and depth of analysis for discovery and translational work, while diagnostic laboratories emphasize throughput, regulatory compliance, and reproducibility. Hospitals integrate testing into clinical workflows and prioritize turnaround time and clinical reporting, whereas pharmaceutical companies focus on companion diagnostic alignment with therapeutic pipelines and clinical trial integration. Distribution channel segmentation further affects market access, with direct tender arrangements supporting institutional procurement, distributor sales facilitating broader geographic reach, and online sales enabling rapid ordering of kits and consumables for decentralized testing environments. Together, these segmentation dimensions provide a layered view of product-market fit and guide prioritization of development, commercialization, and customer support investments.

How regional healthcare infrastructure, regulatory approaches, and strategic partnerships drive differentiated adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific

Regional dynamics in companion diagnostics are shaped by distinct healthcare infrastructures, regulatory approaches, and investment ecosystems. In the Americas, integrated healthcare providers, robust clinical trial networks, and a large biotechnology sector foster early adoption of novel diagnostics and close clinician-industry collaboration. This environment supports iterative validation and clinical utility studies that bridge research findings with clinical pathways, while reimbursement dialogues increasingly center on value demonstration and outcome alignment.

Europe, the Middle East & Africa display heterogeneous adoption curves influenced by diverse regulatory regimes and payer landscapes. Robust academic centers and centralized public health systems in parts of Europe facilitate multicenter collaborations and standardization efforts, whereas markets across the Middle East and Africa often emphasize capacity building, laboratory infrastructure modernization, and regional harmonization. Cross-border partnerships and diagnostic hubs play a vital role in extending advanced testing capabilities to broader patient populations in these regions.

The Asia-Pacific region is notable for rapid investment in laboratory infrastructure, growing domestic diagnostic manufacturing, and large patient cohorts that enable translational research and real-world evidence generation. Government-led initiatives to expand precision medicine programs and the presence of high-volume clinical sites create opportunities for scaling diagnostic services. Across regions, stakeholders must navigate differing regulatory timelines, reimbursement frameworks, and infrastructure constraints, tailoring market entry and partnership strategies to regional realities while leveraging global evidence generation to support broader adoption.

Insights into competitive positioning, partnerships, and capability stacks that determine success for diagnostic developers, laboratories, and integrated service providers

Competitive dynamics in companion diagnostics are shaped by a mix of specialized assay developers, instrument manufacturers, clinical laboratory networks, and integrated diagnostic-therapeutic partnerships. Companies with deep expertise in analytical chemistry, molecular biology, or pathology have leveraged proprietary platforms and validated workflows to establish clinical credibility. At the same time, firms that combine scalable manufacturing, regulatory experience, and collaborative development models have shown an ability to accelerate clinical translation and market entry for companion tests.

Strategic collaborations between diagnostic developers and pharmaceutical sponsors remain a critical pathway for co-developing tests that align tightly with therapeutic modalities. These partnerships often extend into evidence generation, coding and reimbursement strategy, and post-market surveillance. In addition, laboratory service providers that deliver end-to-end testing capabilities, including centralized and distributed service models, play a vital role in bridging innovation with clinical access. Companies that invest in robust quality systems, interoperability with electronic health records, and clinician-facing reporting tools tend to achieve stronger adoption and integration into care pathways.

Emerging competitive pressure comes from firms that combine diagnostics with advanced analytics and decision-support solutions, enabling more actionable, longitudinal interpretations of biomarker data. These hybrid offerings suggest the market is shifting toward value propositions that marry analytical performance with clinical utility and workflow efficiency, rewarding organizations that can demonstrate tangible improvements in patient management and health system outcomes.

Actionable strategic imperatives for diagnostic developers and health systems to align innovation, supply chain resilience, and collaborative evidence generation

Industry leaders should prioritize a few strategic imperatives to navigate the evolving diagnostics environment effectively. First, align product development with demonstrable clinical utility and operational feasibility by embedding end-user needs into assay design, validating performance across representative workflows, and ensuring reporting outputs integrate with clinical decision-making processes. This alignment reduces adoption friction and supports payer discussions focused on outcome improvements rather than analytic novelty.

Second, strengthen supply chain resilience by diversifying suppliers, considering regional manufacturing or assembly where feasible, and incorporating tariff and logistics scenarios into procurement planning. Proactive vendor partnerships and long-term agreements with contingency clauses can reduce exposure to trade and distribution disruptions and support reliable laboratory operations.

Third, cultivate strategic collaborations with pharmaceutical sponsors, clinical networks, and health systems to co-generate evidence and accelerate clinical integration. These collaborations should be structured to share risks and align incentives around demonstrable patient benefits. Investing in data infrastructure and analytics capabilities enables more persuasive real-world evidence generation and continuous performance monitoring.

Finally, invest in commercialization models that reflect end-user realities, including hybrid distribution approaches that combine direct institutional engagement, distributor partnerships, and digital channels for consumables. Complementing product innovation with clinician education, payer engagement plans, and streamlined regulatory strategies will increase the likelihood of successful uptake and sustained clinical use.

A transparent mixed-methods research framework combining expert interviews, regulatory document analysis, and case study synthesis to derive actionable diagnostic insights

The research approach blends qualitative and quantitative techniques to produce a comprehensive understanding of the companion diagnostics landscape. Primary inputs include interviews with clinical thought leaders, laboratory directors, regulatory experts, and commercial stakeholders to capture operational challenges, adoption drivers, and unmet clinical needs. These conversations inform a framework for evaluating analytical platforms, assay performance characteristics, and integration barriers within real-world clinical workflows.

Secondary research encompasses a broad review of peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and public policy statements to ground the analysis in current scientific and regulatory context. Comparative case studies of successful diagnostic-therapeutic co-development efforts were analyzed to extract best practices and common pitfalls in evidence generation, regulatory strategy, and market access planning.

Synthesis involved triangulating primary and secondary findings to develop scenario-based implications for supply chain design, commercialization pathways, and regional entry strategies. Validation workshops with industry stakeholders were used to refine conclusions and ensure practical relevance. This mixed-methods design emphasizes transparency in assumptions, traceability of insights to source inputs, and actionable recommendations tailored to organizational decision-making needs.

Concise conclusion synthesizing technological, regulatory, and commercial imperatives to guide strategic investments and clinical integration of companion diagnostics

In summary, companion diagnostics are increasingly central to precision medicine, reshaping clinical pathways, trial designs, and commercial models. Technological advancements in sequencing and assay multiplexing, coupled with evolving regulatory and reimbursement dialogues, are elevating the expectations for clinical utility and operational readiness. Supply chain and trade policy dynamics add complexity, making resilience and strategic sourcing essential components of commercialization planning.

Segmentation across product type, application, end user, and distribution channel highlights distinct development and go-to-market requirements, while regional dynamics require tailored strategies that reflect infrastructure, regulatory, and payer differences. Competitive advantage accrues to organizations that combine analytical excellence with robust evidence generation, strategic partnerships, and clinician-aligned reporting and workflow integration. Taken together, these insights provide a coherent foundation for leaders seeking to prioritize investments and accelerate clinical integration of companion diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiomic biomarkers into companion diagnostic assays for personalized therapies
  • 5.2. Expansion of liquid biopsy based companion diagnostics for real-time treatment monitoring
  • 5.3. Adoption of digital pathology and AI algorithms in companion diagnostic result interpretation
  • 5.4. Collaboration between pharmaceutical and diagnostic developers for co-development of targeted therapies
  • 5.5. Emergence of cost-effective point-of-care companion diagnostic platforms in emerging markets
  • 5.6. Regulatory harmonization initiatives to streamline companion diagnostic approvals across major regions
  • 5.7. Development of multiplex companion diagnostics enabling simultaneous profiling of multiple biomarkers
  • 5.8. Growing investment in next-generation sequencing panels for comprehensive companion diagnostic testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Diagnostics Market, by Product Type

  • 8.1. Immunohistochemistry
  • 8.2. In Situ Hybridization
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Digital Pcr
    • 8.4.2. Quantitative Pcr

9. Companion Diagnostics Market, by Application

  • 9.1. Genetic Disorders
  • 9.2. Infectious Diseases
  • 9.3. Oncology
  • 9.4. Pharmacogenomics

10. Companion Diagnostics Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Pharmaceutical Companies

11. Companion Diagnostics Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distributor Sales
  • 11.3. Online Sales

12. Companion Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. QIAGEN N.V.
    • 15.3.4. Abbott Laboratories
    • 15.3.5. Illumina, Inc.
    • 15.3.6. Danaher Corporation
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. bioMerieux SA
    • 15.3.9. Agilent Technologies, Inc.
    • 15.3.10. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 274. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 275. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. GCC COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS COMPANION DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 314. G7 COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION